Literature DB >> 10712412

Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.

H Sjöland1, D T Eitzman, D Gordon, R Westrick, E G Nabel, D Ginsburg.   

Abstract

Impaired fibrinolysis has been linked to atherosclerosis in a number of experimental and clinical studies. Plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of plasminogen activation and has been proposed to promote atherosclerosis by facilitating fibrin deposition within developing lesions. We examined the contribution of PAI-1 to disease progression in 2 established mouse models of atherosclerosis. Mice lacking apolipoprotein E (apoE-/-) and mice lacking the low density lipoprotein receptor (LDLR-/-) were crossbred with transgenic mice overexpressing PAI-1 (resulting in PAI-1 Tg(+)/apoE-/- and PAI-1 Tg(+)/LDLR-/-, respectively) or were crossbred with mice completely deficient in PAI-1 gene expression (resulting in PAI-1-/-/apoE-/- and PAI-1-/-/LDLR-/-, respectively). All animals were placed on a western diet (21% fat and 0.15% cholesterol) at 4 weeks of age and analyzed for the extent of atherosclerosis after an additional 6, 15, or 30 weeks. Intimal and medial areas were determined by computer-assisted morphometric analysis of standardized microscopic sections from the base of the aorta. Atherosclerotic lesions were also characterized by histochemical analyses with the use of markers for smooth muscle cells, macrophages, and fibrin deposition. Typical atherosclerotic lesions were observed in all experimental animals, with greater severity at the later time points and generally more extensive lesions in apoE-/- than in comparable LDLR-/- mice. No significant differences in lesion size or histological appearance were observed among PAI-1-/-, PAI-1 Tg(+), or PAI-1 wild-type mice at any of the time points on either the apoE-/- or LDLR-/- genetic background. We conclude that genetic modification of PAI-1 expression does not significantly alter the progression of atherosclerosis in either of these well-established mouse models. These results suggest that fibrinolytic balance (as well as the potential contribution of PAI-1 to the regulation of cell migration) plays only a limited role in the pathogenesis of the simple atherosclerotic lesions observed in the mouse.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712412     DOI: 10.1161/01.atv.20.3.846

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  22 in total

Review 1.  The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.

Authors:  A Luttun; M Dewerchin; D Collen; P Carmeliet
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

2.  PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice.

Authors:  K Tordjman; C Bernal-Mizrachi; L Zemany; S Weng; C Feng; F Zhang; T C Leone; T Coleman; D P Kelly; C F Semenkovich
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

3.  Visualization of endothelial barrier damage prior to formation of atherosclerotic plaques.

Authors:  Heike Bömmel; Florian Kleefeldt; Alma Zernecke; Sharang Ghavampour; Nicole Wagner; Stefanie Kuerten; Süleyman Ergün
Journal:  Histochem Cell Biol       Date:  2017-03-25       Impact factor: 4.304

4.  Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts.

Authors:  Yan Ji; Tammy L Strawn; Elizabeth A Grunz; Meredith J Stevenson; Alexander W Lohman; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05-12       Impact factor: 8.311

5.  Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1.

Authors:  V A Ploplis; I Cornelissen; M J Sandoval-Cooper; L Weeks; F A Noria; F J Castellino
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

6.  The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques.

Authors:  Alessandra Barazza; Courtney Blachford; Orli Even-Or; Victor A Joaquin; Karen C Briley-Saebo; Wei Chen; Xian-Cheng Jiang; Willem J M Mulder; David P Cormode; Zahi A Fayad; Edward A Fisher
Journal:  Bioconjug Chem       Date:  2013-05-10       Impact factor: 4.774

7.  Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.

Authors:  Hekmat B Khoukaz; Yan Ji; Drew J Braet; Manisha Vadali; Ahmed A Abdelhamid; Cory D Emal; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

Review 8.  The hemostasis system in murine atherosclerosis.

Authors:  Takayuki Iwaki; Victoria A Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

Review 9.  The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.

Authors:  Hunjoo Ha; Eun Y Oh; Hi B Lee
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

10.  The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque.

Authors:  Mary Drinane; Jessica Mollmark; Lyubomir Zagorchev; Karen Moodie; Baiming Sun; Amy Hall; Samantha Shipman; Peter Morganelli; Michael Simons; Mary Jo Mulligan-Kehoe
Journal:  Circ Res       Date:  2009-01-02       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.